Vision and Mission

Our vision is to be the most valuable nuclear medicine company in China, as well as a trusted leader in the world.

Bring hope to patients with the most innovative nuclear medicine diagnostic and therapeutic products.

Suzhou Smart Nuclide Pharmaceutical Technology Company was founded in 2015, our aim is to provide innovative diagnostic and therapeutic radiopharmaceuticals for patients around the world. Our products focus on thyroid cancer, precision radioactive imaging and targeted radioligand therapy. Since its foundation, Smart Nuclide has raised over 200 million yuan with four rounds of venture capital investment.
In Smart Nuclide, we build several technology platforms focusing on the discovery, R&D, and production of radiopharmaceuticals based on single-domain antibody, with independent intellectual property rights...